Septerna

Septerna EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Septerna (SEPN) as of Oct 25, 2026 is -8.65. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -9.15 — a change of -5.40% (higher).

EV/EBITDA

-8.65

YoY

-5.40%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Septerna is 2025 -8.65 . EV/EBITDA (Enterprise Value to EBITDA) of Septerna was 2024 -9.15 . It decreases by -5.40% higher compared to the previous year.

The Septerna EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2022
-37.89 USD
Jan 1, 2023
482.82 USD
Jan 1, 2024
-9.15 USD
Jan 1, 2025
-8.65 USD
The Septerna EV/EBITDA history
YEAREV/EBITDAYoY
-8.65-5.40%
-9.15-101.89%
482.82-1,374.20%
-37.89—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Septerna Stock analysis

What does Septerna do? Septerna, Inc. develops oral small molecule GPCR-targeted drugs using its proprietary Native Complex PlatformTM. The company focuses on endocrinology, immunology, and inflammation, and metabolic diseases. Its pipeline targets GPCRs for the first time, uncovering novel binding pockets and pursuing various pharmacologies like agonists and antagonists. The firm advances a deep portfolio of programs for patients with significant unmet needs. Septerna's products are developed for pharmaceutical companies seeking novel drug discovery platforms. The company's Native Complex PlatformTM enables industrial-scale GPCR targeting, offering solutions for diseases with high unmet medical needs. Its therapeutic areas include endocrinology, immunology, and inflammation, and metabolic diseases, targeting patients requiring innovative treatments. The company's pipeline includes oral small molecule drug candidates for GPCR-targeted therapies. These candidates are designed to address conditions in endocrinology, immunology, and inflammation, and metabolic diseases. Septerna's approach focuses on uncovering novel binding pockets and pursuing diverse pharmacologies to achieve therapeutic effects. The firm's programs target patients with significant unmet needs across multiple therapeutic areas. Septerna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Septerna stock

EV/EBITDA (Enterprise Value to EBITDA) of Septerna is -8.65 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Septerna changed from -9.15 to -8.65, representing a -5.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Septerna since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Septerna with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Septerna

All Key Metrics — Septerna